Literature DB >> 8705756

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

T J Bowker1, T C Clayton, J Ingham, N R McLennan, H L Hobson, S D Pyke, B Schofield, D A Wood.   

Abstract

OBJECTIVE: To measure the potential for secondary prevention of coronary disease in the United Kingdom.
DESIGN: Cross sectional survey of a representative sample of coronary patients from a retrospective review of hospital medical records and patient interview and examination.
SETTING: Stratified random sample of 12 specialist cardiac centres and 12 district general hospitals drawn from 34 specialist cardiac centres and 261 district general hospitals in 12 geographic areas in the United Kingdom.
SUBJECTS: 2583 patients < or = 70 yr; 25 consecutive males and 25 consecutive females identified retrospectively in each of four diagnostic categories: coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, acute myocardial infarction, and acute myocardial ischaemia without evidence of infarction. MAIN OUTCOME MEASURES: Risk factor recording and management in medical records; the prevalence and control of risk factors at interview six months after the procedure or event.
RESULTS: Recording of coronary risk factors in patient's records was incomplete and this varied by risk factor. Smoking habit and blood pressure were most completely recorded, whereas a history of hyperlipidaemia and blood cholesterol concentrations were least complete. Risk factor records were more likely to be complete in cardiac centres than in district hospitals. At interview 10% to 27% of patients were still smoking cigarettes and 75% remained overweight, females more severely so. Up to a quarter of patients remained hypertensive, males more severely so than females. Over three quarters had a total cholesterol > 5.2 mmol/l. In patients on medication for blood pressure, cholesterol or glucose, risk factor profiles were little better than in those who were not. Only about one patient in three was taking a beta blocker after infarction. Up to a fifth of patients who had had acute myocardial ischaemia were not taking aspirin at follow up.
CONCLUSIONS: There is considerable potential to reduce the risk of a further major ischaemic event in patients with established coronary disease. This can be achieved by effective lifestyle intervention, the rigorous management of blood pressure and cholesterol, and the appropriate use of prophylactic drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8705756      PMCID: PMC484305          DOI: 10.1136/hrt.75.4.334

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  11 in total

1.  An overview of randomized trials of rehabilitation with exercise after myocardial infarction.

Authors:  G T O'Connor; J E Buring; S Yusuf; S Z Goldhaber; E M Olmstead; R S Paffenbarger; C H Hennekens
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

2.  The effect of warfarin on mortality and reinfarction after myocardial infarction.

Authors:  P Smith; H Arnesen; I Holme
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

3.  Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).

Authors:  M L Burr; A M Fehily; J F Gilbert; S Rogers; R M Holliday; P M Sweetnam; P C Elwood; N M Deadman
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

Review 4.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

Authors:  K Pyörälä; G De Backer; I Graham; P Poole-Wilson; D Wood
Journal:  Eur Heart J       Date:  1994-10       Impact factor: 29.983

5.  Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

Authors:  D J Betteridge; P M Dodson; P N Durrington; E A Hughes; M F Laker; D P Nicholls; J A Rees; C A Seymour; G R Thompson; A F Winder
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

6.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.

Authors:  P Sever; G Beevers; C Bulpitt; A Lever; L Ramsay; J Reid; J Swales
Journal:  BMJ       Date:  1993-04-10

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.

Authors:  M de Lorgeril; S Renaud; N Mamelle; P Salen; J L Martin; I Monjaud; J Guidollet; P Touboul; J Delaye
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

9.  Cessation of smoking after myocardial infarction. Effects on mortality after 10 years.

Authors:  A Aberg; R Bergstrand; S Johansson; G Ulvenstam; A Vedin; H Wedel; C Wilhelmsson; L Wilhelmsen
Journal:  Br Heart J       Date:  1983-05

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

View more
  46 in total

1.  Treatment of myocardial infarction should be audited before heart failure clinics are set up.

Authors:  A D Timmis
Journal:  BMJ       Date:  1999-07-10

2.  Switching to statins: a challenge for primary care.

Authors:  N G Fisher; A J Marshall; J Went
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

Review 3.  Development and evaluation of complex interventions in health services research: case study of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group.

Authors:  F Bradley; R Wiles; A L Kinmonth; D Mant; M Gantley
Journal:  BMJ       Date:  1999-03-13

4.  Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK.

Authors:  D Monkman
Journal:  BMJ       Date:  2000-11-25

5.  Ten year audit of secondary prevention in coronary bypass patients.

Authors:  R J Irving; S H Oram; J Boyd; P Rutledge; F McRae; P Bloomfield
Journal:  BMJ       Date:  2000-07-01

6.  Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales.

Authors:  L S Cozma; A Ogunko; A Rees
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

7.  Secondary prevention in 24, 431 patients with coronary heart disease: survey in primary care.

Authors:  A J Brady; M A Oliver; J B Pittard
Journal:  BMJ       Date:  2001-06-16

8.  Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records.

Authors:  J Gray; A Majeed; S Kerry; G Rowlands
Journal:  BMJ       Date:  2000-09-02

9.  Reducing the risk of recurrent coronary heart disease. We know a bit more about what doesn't work.

Authors:  F Bradley; M E Cupples
Journal:  BMJ       Date:  1999-06-05

10.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.

Authors:  S R Majumdar; J H Gurwitz; S B Soumerai
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.